Olanzapine Anorexia Nervosa: Session Watch List

Authored by Dr. Hannah Lin, counseling psychologist trained in CBT, ACT, and IFS, with over a decade of clinical practice across anxiety and complex trauma.

It is Tuesday at 4:10. Maya is late. She sits down already half-asleep and asks whether the medicine will make her huge. The psychiatrist started olanzapine last month. You did not. The question in this hour is not “what dose.” The question is what you saw, why it belongs on the team thread, and what you will send before you write the note.

In olanzapine anorexia nervosa care, fill the watch list from this hour and keep a blank copy for the next one. Use the 2019 trial as a reference point: it found a modest BMI change, not an added psychological benefit. Then send the pass-on line. Technique selection stays on eating disorder therapy techniques. Do not use this watch list as a substitute for CBT-E, DBT-informed skills, or family-informed support.

Educational content for licensed therapists, not clinical, legal, or prescribing advice. Olanzapine for anorexia nervosa is off-label. Dose, labs, and whether to continue belong to the prescriber. You observe, ask, and pass on.

What the trial actually showed

The label you will see named in a team meeting is still the schizophrenia and bipolar I label. Anorexia nervosa is not an approved use on that label. That is not a therapy decision. It is a medical one. Psychotherapy stays the work you are already running. When a prescriber adds olanzapine, it sits beside that work.

The trial you will hear cited is Attia and colleagues (2019): 152 adult outpatients, weekly visits for 16 weeks, olanzapine versus placebo. BMI rose faster on olanzapine. The Yale-Brown Obsessive Compulsive Scale obsession score did not. Abnormal metabolic blood tests were not more common in the olanzapine group in that sample. The authors called the weight effect modest. They also said psychological symptoms did not separate from placebo.

So what? You should not expect the medicine to do the shape-and-weight work for you. Attia called the BMI effect modest and said psychological symptoms did not separate from placebo. If she is skipping snacks between sessions, treat that as a team fact in this hour, not as proof the trial result arrived or failed.

Fact	Attia 2019
Who	152 adult outpatients, 16 weeks
Weight	BMI rose faster on olanzapine than placebo
Psychological symptoms	No significant YBOCS difference
Metabolic labs	No significant group difference in abnormal tests
Care around the pill	Weekly visits, not medication alone

Those cells are the whole result. Do not turn them into a promise that olanzapine anorexia nervosa treatment “fixes” the illness.

What you watch in the hour

In olanzapine anorexia nervosa care, you are not the scale. You are not the lab. You are the person who sees whether the hour still has a client in it.

Use the watch list to organize three things: the cue, why it matters, and who needs it. Keep the handoff concise. When a cue needs more clinical context, document it in the relevant sedation, restriction, or metabolic section before sending it on.

Cue	Why it matters	Pass to
Scale talk, clothes, “I look huge”	Weight is the trial signal	Prescriber and dietitian: the comment, not a dose
Skipped snack after a “too-big” meal	Between-session undoing is a team fact	Whole team, same day
Dozing, late, flat affect from sleep	Sedation cuts engagement	Prescriber: timing and sleep, no milligram idea
Thirst, night urination, unusual fatigue	Metabolic warnings live on the FDA label	Prescriber: the cue, and whether labs are due
Missed or extra doses	Adherence is a medical fact	Prescriber: what they reported taking
Restlessness, inner pace they cannot sit with	Akathisia belongs in the medical note	Prescriber: when it started

Did the hour get quieter because the work landed, or because she was falling asleep? That one distinction is worth more than a paragraph of “client engaged.”

Sedation and engagement

• What to watch: Late arrival, dozing, answers that trail off, a request to end early “because I cannot keep my eyes open.”

• Why it matters: The FDA label flags somnolence and impaired alertness. If the hour is lost to sleep, CBT-E monitoring and chain work do not happen. The medicine is then competing with the therapy it was supposed to sit beside.

• What to pass on: Clock times. How much of the hour was usable. Whether she can get home safely. No suggestion that anyone “drop the dose.”

Weight comments and compensatory restriction

• What to watch: “The medicine is making me huge.” A snack skipped to even out breakfast. An extra walk that was not on the plan. Clothes comments that arrived this week, not last month.

• Why it matters: Attia found a modest BMI rise and no extra movement on obsessionality. In the hour, treat a skipped snack after a meal that felt too big as a team fact, not as proof the medicine failed.

• What to pass on: The comment in her words. The skipped meal or extra movement. Whether the dietitian already knows. Still no milligram idea.

Metabolic cues you can hear without a lab

• What to watch: New thirst, night urination, unusual fatigue, “my mouth is always dry,” a family comment about sugars.

• Why it matters: The FDA label warns about hyperglycemia, dyslipidemia, and weight gain. Attia did not see more abnormal blood tests in the olanzapine group. That is not a reason to ignore a new thirst history in your office. You are not confirming diabetes. You are not sitting on the cue.

• What to pass on: The new symptom, when it started, and whether she has a lab visit already booked. The prescriber decides what to order.

What you pass on, and what you do not

Write the pass-on the same day. A Friday observation that waits until Monday is a different clinical fact.

A usable line looks like Maya’s: late, dozing, skipped snack, thirst, night urination, fear of getting huge, no dose idea, next medical date requested.

An unusable line looks like “consider increasing olanzapine” or “client tolerating well.” The first is prescribing. The second could sit on any chart.

You do not:

• Name a milligram, a titration step, or a hold
• Tell her to skip tonight’s dose
• Trade the medicine against a therapy technique as if they were the same lever
• Promise the team that you are watching her between sessions

You do:

• Quote her words
• Name the engagement cost
• Flag compensatory restriction
• Send metabolic and sedation cues to the person who owns labs and timing

The standing plan still needs the medical clinician, the dietitian, and the stabilization threshold already written. If that document does not exist, stop adding watch lists and go back to the eating disorder treatment plan template.

What belongs in the therapy note

The chart needs the observation, the function, and the pass-on. It does not need a pharmacology essay.

That note shows why you stayed on coordination this week. It does not pretend you adjusted the medicine.

When you want that structure drafted from the watch list and the pass-on, AI clinical notes can hold the sequence. You still decide what is safe to write. You still sign it.

When to skip the watch list

Skip the watch list and escalate when the hour is no longer outpatient-safe: syncope, chest pain, a resting heart rate the medical clinician has already named as a stop, a sudden drop in weight, or a client too sedated to leave safely. Those are medical events. Call the team. Do not add another row.

Skip the watch list when no prescriber is on the team. Olanzapine anorexia nervosa work without a medical owner is not a therapy plan. Refer.

Skip the watch list when the real job is technique selection, FBT coaching you are not trained to do, or fluoxetine for binge-purge work. That last job lives on Prozac for bulimia. Do not stretch this watch list across those jobs.

Attia enrolled adult outpatients. Those cells are adult outpatient cells. If the prescriber is using olanzapine with a younger client, your pass-on still matters. Keep the trial speech inside the sample it came from.

Keep the watch list next to the hour

Copy Maya’s three fields or the blank list. Fill them before you stand up. Send the pass-on. Then write the note.

Emosapien does not prescribe, read labs, or replace the psychiatrist. It keeps the observation, the team message, and the next-hour plan in one chart so the coordination step does not live in a sticky note.

References